Fragmentation and defragmentation of the law on biomedical innovations

  • Mahalatchimy, Aurelie (Primary Chief Investigator (PCI))
  • Brosset, Estelle (Chief Investigator (CI))
  • Gay, Laurence (Chief Investigator (CI))
  • Magnon, Xavier (Chief Investigator (CI))
  • Maljean-Dubois, Sandrine (Chief Investigator (CI))
  • Perron, Martine (Chief Investigator (CI))
  • Rubio, Nathalie (Chief Investigator (CI))
  • Bernardot, Marc (Chief Investigator (CI))
  • Chabannon, Christian (Chief Investigator (CI))
  • Sabatier, Florence (Chief Investigator (CI))
  • Gardner, John (Chief Investigator (CI))
  • Flear, Mark (Chief Investigator (CI))
  • Morrison, Michael (Chief Investigator (CI))

Project: Research

Project Details

Project Description

European law (including the laws of the European Union, Council of Europe, and European Patent Organisation) on biomedical innovations (BI), in areas such as gene therapy, regenerative medicine, or nanomedicine, involves two contrasting processes: fragmentation (division or segmentation), and defragmentation (gathering together, connecting or ‘harmonising’).

At the crossroads between social and human sciences (Law, Sociology and Science and Technology Studies) and biomedical sciences (Pharmaceutical Sciences, Biomedical Sciences), I-BioLex aims to explore and explain these legal processes and provide histories of successive developments of both processes in European law on biomedical innovations
Short titleI-BioLex
Effective start/end date1/02/211/10/24


  • Agence Nationale de la Recherche (ANR): A$498,058.00